Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Phase 4

• Conditions: Advanced Non-squamous NSCLC
• Interventions: Drug: Anlotinib Hydrochloride

• Registration Number: NCT03778853
• Lead Sponsor: LanZhou University

Brief Summary

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.

Detailed Description

It is an open, single-arm, multi-center clinical trial conducted in China, and plan to Recruiting 72 patients in the elderly without systemic chemotherapy. Patents receive 12mg anlotinib orally daily on day 1to 14 of a 21-day cycle until progression of disease, assess safety and efficacy of the drug.

Study Timeline

• Status Verified: 2018-12
• Study First Submitted: 2018-12-15
• Study First Submitted QC: 2018-12-15
• Last Update Submitted: 2018-12-15
• Study First Posted: 2018-12-19
• Last Update Posted: 2018-12-19
• Study Start: 2019-01
• Primary Completion: 2019-12
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Signed and dated informed consent
• Age：≥70
• Subjects with histologically or cytologically confirmed locally advanced and/or advanced NSCLC
• at least two systematic chemotherapy with upwards of 1-line treatments or cannot suffer
• The negative patients in EGFR&ALK can participate or who positive in EGFR&ALK, have or have not drug tolerance after the treatment with relative targeted drugs
• Subjects with at least one measurable lesion as defined by RECIST (version 1.1)
• Expected Survival Time: Over 3 months
• ECOG PS：0-1
• main organs function is normal

Exclusion Criteria

• 1.Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
• lung squamous carcinoma
• Other active malignancies requiring treatment
• History of malignancy
• Have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included
• Abnormal coagulation (INR>1.5 or PT>ULN+4s or APTT >1.5 ULN); Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation
• take major surgical treatments or have serious trauma before grouping, or the impact of surgery or trauma has been eliminated for less than 14 days
• Patients with active or unable to control serious infections
• Patients with Grade II or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc male ≥ 450 ms, female ≥ 470 ms) ; Patients with grade III to IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) <50% (NYHA Classification)
• Patients with non-healing wounds or fractures
• with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus).
• get arterial/venous thrombosis within 12 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism
• Patients with cirrhosis, decompensated liver disease, or active hepatitis Have suffered from hemorrhagic disease or coagulation dysfunction
• diagnosed with disease which will severely endanger the security of patients or influence the completion of this research

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Anlotinib Hydrochloride	Anlotinib Hydrochloride	Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent

Primary Outcome Measures

Name	Time	Method
PFS	Time Frame: each 42 days up to PD or death(up to 24 months)	Progress free survival (PFS)

Secondary Outcome Measures

Name	Time	Method
OS	From randomization until death (up to 24 months)	Overall Survival (OS)
ORR	each 42 days up to intolerance the toxicity or PD (up to 24 months)	Objective Response Rate (ORR)
DCR	each 42 days up to intolerance the toxicity or PD (up to 24 months)	Disease Control Rate (DCR)
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Until 30 day safety follow-up visit	Number of Participants with Adverse Events as a Measure of Safety and Tolerability
EORTC QLQ-C30	each 42 days up to intolerance the toxicity or PD (up to 24 months)	use EORTC QLQ-C30(version 3) questionnaire to evaluate the quality of life